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Volume 59, Number 6S Abstracts 37Saneurysm (AAA) but is associated with more late reinter-
ventions compared with open repair. This study compares
the outcomes from EVAR and open repair in the Vascular
Study Group of New England (VSGNE).
Methods: We reviewed all elective, nonruptured
symptomatic, and ruptured endovascular and open repairs
of AAA from 2003-2012. Postoperative reinterventions,
morbidity, and mortality were compared at the 30-day,
30-day to 1-year, and overall 1-year follow-up.
Results: We identiﬁed 3347 EVARs and 2251 open
repairs. At 30 days and 1 year, overall reintervention rates
were higher after open repair compared with EVAR (Ta-
ble). Between 30 days and 1 year, reinterventions were
less after elective open repair compared with EVAR (2.6%
vs 3.8%, P ¼ .03) but were similar after open repair and
EVAR for symptomatic (4.5% vs 4.6%, P ¼ .97) and
ruptured (5.5% vs 4.3%, P ¼ .58) AAA. Mortality was
lower after elective EVAR compared with open repair at
30 days (1.6% vs 2.6%, P ¼ .01) but was similar at 1 year
(7.2% vs 7.3%, P ¼ .88).
Conclusions: Reintervention was more common after
open repair compared with EVAR across all AAA repair in
the perioperative period. Between 30 days and 1 year,
EVAR had higher reintervention rates for elective AAA
repair but was similar to open repair for symptomatic and
ruptured AAA.
Table. Reintervention rates for all patients undergoing
endovascular aneurysm repair (EVAR) vs open
abdominal aortic aneurysm repair
EVAR Open
Reinterventions (n ¼ 3347) (%) (n ¼ 2251) (%) P30-day reinterventions 1.9 11.5 <.01
Multiple reinterventions 0.3 2.2 <.01
Leg embolization 0.8 1.6 <.01
Bowel ischemia 0.5 2.5 <.01
Wound complication 0.4 3.1 <.01
Hemorrhage 0.6 2.7 <.01
Return to operating room 10.8 10.9 <.01(n ¼ 3002) (n ¼ 2140)
30-day to 1-year reinterventions 3.8 3.3 .29
Multiple reinterventions 1.3 0.6 <.01
Total 1-year reinterventions 5.5 13.2 <.01Author Disclosures: R. Bensley: Nothing to disclose; C.
Feng: Nothing to disclose;M. Schermerhorn: Nothing to
disclose.
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Objectives: The purpose of this study is to determine
the cost differences associated with different intravenous
(IV) blood pressure medications used in the treatment of
acute Stanford type B aortic dissections.
Methods: A retrospective record review was conduct-
ed of patients treated for an acute type B aortic dissection
between June 2006 and September 2013 to determinethe IV blood pressure medication regimen (a combination
of labetalol, esmolol, nitroprusside, and/or nicardipine).
Patients receiving each IV infusion were compared with pa-
tients not receiving that drug with regards to the total cost
of the infusion, mortality, the complication rate associated
with the dissection, and the need for operation.
Results: Ninety patients were treated with IV blood
pressure medications for an acute type B dissection. The
in-hospital mortality rate was 11.1%, 33.3% experienced a
complication of their dissection, and 4.4% had an operation
after an initial attempt at medical therapy. Fifty-three
percent of patients received an esmolol infusion, 46% a
nicardipine infusion, 41% a labetalol infusion, and 54% a
nitroprusside infusion. Median cost of admission was
$66,355 (interquartile range, $41,372-$160,176), and
median cost of the infusions was $4837 (interquartile
range, $1922-$13,240). Esmolol was associated with
increased total drug cost (median, $10,545 vs $1947; P
< .001) and longer intensuve care unit (ICU) stays (me-
dian, 5 vs 3 days; P ¼ .025). Nicardipine carried increased
cost ($11,195 vs $3365, P < .001) and longer ICU stay (5
vs 3 days, P ¼ .058). Labetalol carried decreased cost (me-
dian $3931 vs $9136, P ¼ .004) with no difference in ICU
stay (3 vs 3 days; P ¼ .175). Nitroprusside carried no dif-
ference in cost ($5095 vs $4038; P ¼ .182). No drug
was associated with increased mortality, need for operation,
or complication of the dissection.
Conclusions: Labetalol and nitroprusside are signiﬁ-
cantly cheaper medications to treat acute type B aortic dis-
sections, and they are not associated with increased risk of
death, complication of the dissection, or need for
operation.
Author Disclosures: K. Maxﬁeld: Nothing to disclose;
T. Naslund: W. L. Gore, Aptus Endosystems, and
CVRx, consulting fees or other remuneration (payment);
A. Richter: Nothing to disclose; C. Sheng: Nothing to
disclose.
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Objectives: We sought to demonstrate the prognostic
implication of ﬂap thickness (FT) in type B aortic dissection
(TBAD).
Methods: A retrospective review was undertaken of all
patients with TBAD from June 2006 to June 2012. Demo-
graphics, hospital course, imaging, and follow-up visits
were analyzed. FT on computed tomography angiography
(CTA) was measured using full width at half maximum
technique. Survival rates and predictors of outcome were
determined using the Kaplan-Meier method with Cox pro-
portional hazards.
Results: Of 134 patients with TBAD, 101 (75%) had a
classical dissection and 33 (24%) had atypical dissection (no
dissection ﬂap). FT analysis was available in 63 patients (38
men), with a mean age of 646 15 years. Median follow-up
was 33 (0-135) months. Sixteen patients underwent
